Baidu
map

PAIN:SUD及非SUD患者停用长期阿片类药物治疗的原因分析

2017-02-15 MedSci MedSci原创

有一些因素可能促进患者服用阿片类药物过程中发生停药,包括缺乏对阿片类药物减轻慢性疼痛的长期有效性的认识,对阿片类药物相关不良反应的过度认知,紧密监测阿片类药物相关的异常行为以及对阿片类药物处方的更大限制。在被认为处于“高风险”的患者中,停药率可能最明显。近期,一项发表在PAIN 杂志上的研究旨在比较在美国主要医疗保健系统中,有或没有物质使用障碍(SUD)的患者之间停用长期阿片类药物治疗(LTOT)

有一些因素可能促进患者服用阿片类药物过程中发生停药,包括缺乏对阿片类药物减轻慢性疼痛的长期有效性的认识,对阿片类药物相关不良反应的过度认知,紧密监测阿片类药物相关的异常行为以及对阿片类药物处方的更大限制。在被认为处于“高风险”的患者中,停药率可能最明显。

近期,一项发表在PAIN 杂志上的研究旨在比较在美国主要医疗保健系统中,有或没有物质使用障碍(SUD)的患者之间停用长期阿片类药物治疗(LTOT)的原因。

此项回顾性队列研究汇集了一批退伍军人健康管理局的患者,进行至少连续12个月接受阿片类药物治疗,随后停止阿片类药物治疗至少12个月。从这个队列,研究者们随机选择300例诊断SUD患者和倾向评分匹配的300例无SUD诊断的患者。对患者的医疗记录进行全面的审查以确定LTOT停药的原因。

大多数患者(85%)是由于临床医生,而不是患者的决定而停止的。对于临床医生建议停药的患者,75%由于阿片类药物相关的异常行为而停药。相对于没有SUD的患者,具有SUD的患者由于异常行为(81%对68%)而更有可能中断LTOT,最显着的是滥用酒精或其他物质。

此项研究首次评估了在具有和不具有SUD诊断的患者中停用LTOT的原因。这种高危人群需要同时治疗SUD和慢性疼痛。

原始出处:
Lovejoy TI, Morasco BJ, Demidenko MI, et al. Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders. Pain. 2017 Mar;158(3):526-534. doi: 10.1097/j.pain.0000000000000796. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1253021, encodeId=acee125302147, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Feb 17 12:27:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309037, encodeId=11b9130903eec, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Feb 17 12:27:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176420, encodeId=17b01e642030, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Feb 16 10:14:13 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1253021, encodeId=acee125302147, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Feb 17 12:27:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309037, encodeId=11b9130903eec, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Feb 17 12:27:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176420, encodeId=17b01e642030, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Feb 16 10:14:13 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-02-17 lhlxtx
  3. [GetPortalCommentsPageByObjectIdResponse(id=1253021, encodeId=acee125302147, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Feb 17 12:27:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309037, encodeId=11b9130903eec, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Feb 17 12:27:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176420, encodeId=17b01e642030, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Feb 16 10:14:13 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-02-16 1e10c84am36(暂无匿称)

    文章真心不错耶

    0

Baidu
map
Baidu
map
Baidu
map